亿胜生物科技（股票代码：0474.HK）公告重要交易动态：其全资子公司于7月15日完成减持华泰国际控股（HTICI）股份5.69亿股，交易总额达1.32亿港元。此次股权转让将导致公司财务报表录得约1.354亿港元处置亏损。本次减持后，公司持有华泰国际控股的股权比例将相应降低。市场分析指出，该笔大宗交易可能影响亿胜生物科技当期损益表现，投资者需关注后续财务报告披露的具体影响。港股市场近期频现生物医药企业调整投资组合动作，此次资产处置符合行业战略重组趋势。
亿胜生物科技（股票代码：0474.HK）公告重要交易动态：其全资子公司于7月15日完成减持华泰国际控股（HTICI）股份5.69亿股，交易总额达1.32亿港元。此次股权转让将导致公司财务报表录得约1.354亿港元处置亏损。本次减持后，公司持有华泰国际控股的股权比例将相应降低。市场分析指出，该笔大宗交易可能影响亿胜生物科技当期损益表现，投资者需关注后续财务报告披露的具体影响。港股市场近期频现生物医药企业调整投资组合动作，此次资产处置符合行业战略重组趋势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.